Kinathera Overview

  • Year Founded
  • 2015

Year Founded

  • Status
  • Private

  • Employees
  • 6


  • Latest Deal Type
  • 2ndary - Private

  • Investors
  • 8

Kinathera General Information


Operator of a pharmaceutical company intended to bring a pharmacological therapeutic approach for the treatment of immuno fibrotic autoimmune diseases. The company is developing oral new chemical entities very specific for the inhibition of TBK1 / IKKe in rare immuno-fibrotic diseases such as scleroderma or lupus nephritis with animal proof of concept in therapeutic mode on pulmonary fibrosis and modulation of Type I interferon and autoantibodies, enabling physicians to improve human quality of life.

Contact Information

Formerly Known As
Balmes Transplantation
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Other Industries
Drug Discovery
Primary Office
  • 163 avenue de Luminy, Luminy Biotech Entreprises
  • Bâtiment Béret-Delaage, Case 922
  • 13288 Marseille
  • France
+33 04 00 00 00 00

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Kinathera Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
8. Secondary Transaction - Private 000.00 Completed Pre-Clinical Trials
7. Seed Round 09-Aug-2023 000.00 000.00 In Progress Pre-Clinical Trials
6. Later Stage VC 13-Jun-2022 00000 00.000 Completed Pre-Clinical Trials
5. Seed Round 22-Dec-2017 00000 00000 00.000 Completed Pre-Clinical Trials
4. Angel (individual) 00000 00000 Completed Startup
3. Grant 00000 Completed Startup
2. Accelerator/Incubator Completed Startup
1. Accelerator/Incubator Completed Startup
To view Kinathera’s complete valuation and funding history, request access »

Kinathera Cap Table

Stock # of Shares
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Ordinary Shares 0,000 00.000000 0000.00 0000.00 00 0000.00 00.000
To view Kinathera’s complete cap table history, request access »

Kinathera Patents

Kinathera Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
FR-3095755-A1 New cytoprotective drugs Pending 10-May-2019 000000000 00
AU-2018366352-A1 Novel cytoprotective drugs Inactive 17-Nov-2017 000000000
CA-3079645-A1 Novel cytoprotective drugs Inactive 17-Nov-2017 000000000
EP-3710038-A1 Novel cytoprotective drugs Inactive 17-Nov-2017 000000000
FR-3073738-A1 New cytoprotective medicines Inactive 17-Nov-2017 A61K38/12
To view Kinathera’s complete patent history, request access »

Kinathera Executive Team (2)

Name Title Board Seat Contact Info
Patrick Berna Ph.D Founder, Chief Executive Officer, President & General Manager
Carole Valenti Chief Development Officer
To view Kinathera’s complete executive team members history, request access »

Kinathera Signals

Growth Rate

0.80% Weekly
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers


Similarweb Unique Visitors


Majestic Referring Domains


PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Kinathera Investors (8)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Provence Business Angels Angel Group Minority 000 0000 000000 0
SeedFolio Venture Capital Minority 000 0000 000000 0
Bpifrance Sovereign Wealth Fund 000 0000 000000 0
EUROBIOMED Accelerator/Incubator 000 0000 000000 0
French Government Government 000 0000 000000 0
You’re viewing 5 of 8 investors. Get the full list »